TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01443455

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: videodance
Description: Using a commercially available product called Dance Dance Revolution (DDR) this video-game based dancing system uses a game player, force sensing pad and software. The step sequences are set to a wide range of music and become more complex and frequent as the dancer gains skill. Participants are oriented over 2 weeks. For the rest of the first 3 months, the participant attends at least one supervised session per week. Participants may use the center for additional, unsupervised sessions and/or they can take a dance system home. They also receive brief behavioral intervention sessions for safety orientation, exercise education and adherence promotion. For the following 3 months, the participant enters the transition phase in which she is encouraged to continue to exercise but no formal supervision is provided.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brisk Walking
Description: The overall goal is to increase the duration and speed of walking, using structure and supervision for the first three months, followed by reduced support in the second three months. For the first two weeks, each participant comes to the center at least twice a week to walk.They are encouraged to gradually increase effort and duration to a target of 150 minutes per week of brisk walking.Participants are taught to use Borg's ratings of perceived exertion and self-monitored heart rate to target their level of activity. The next 10 weeks include once weekly supervised sessions and additional sessions either at the center or in preferred community settings. The recommended goal is a minimum of 150 minutes per week of exercise in sessions of at least 10 -15 minutes duration.Participants are given pedometers in order to help them monitor their progress. After 12 weeks, the participant enters a transition phase for a further 3 months.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: delayed entry control
Description: Participants who are randomized to the delayed entry non-exercise control group receive the American Heart Association pamphlet, but no direct support for exercise implementation. After they have completed six months of follow up, they are invited to select any combination of dancing and walking that they prefer and then receive support and instruction according to the protocols described above.~--------------------------------------------------------------------------------
Study: NCT04867655

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orange Juice
Description: Approximately 500 ml of orange juice will be consumed and then blood and urine samples will be collected for 24 hours

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orange juice with either 6g or 3 g of β-Glucan
Description: Approximately 500 ml of orange juice mixed with either 6g or 3 g of β-Glucan will be consumed and then blood and urine samples will be collected for 24 hours
Study: NCT04292405

Intervention type: DEVICE
Intervention: Wearable Cardioverter Defibrillator
Description: Use of the Wearable Cardioverter Defibrillator and AUDICOR AM to evaluate accuracy of cardiac acoustic biomarker recordings.
Study: NCT01592279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin injections
Study: NCT02084368

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nerve block
Description: Patients in this group were assigned to receive lumbar plexus block and sciatic nerve block both using 0.33% ropivacaine 30ml guided by PNS

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Combined spinal and epidural anesthesia
Description: Combined spinal and epidural anesthesia were performed in patients of this group with 0.5% hyperbaric bupivacaine 8\~10mg at L2-3 or L3-4.
Study: NCT02869958

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital action plan for asthma exacerbations + Written action plan
Description: Digital action plan for asthma exacerbation available through an AppWeb and requiring a connected device such as a Smartphone or a tablet computer. The patient must connect and describe the situation to obtain the names, doses and dosing of the treatment his/her physician has recommended for him/her according to the level of severity of the exacerbation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Written action plan
Study: NCT01051583

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diode laser cyclophotocoagulation enhanced by intravitreal injection of Avastin
Description: The operative procedure involved retro-bulbar anesthesia, draping the patient in an aseptic manner, introduction of an eye speculum, 30 laser shots over 270 degrees of the circumference of the limbus. For our study we used the Iris Diode laser machine, the G-probe and we adjusted the settings for 2500 millisecond duration and the 3000 milli-joule and reduced the power progressively until just below the energy level that produced a pop.then after applying the laser, we performed a paracentesis with a 27 gauge needle to soften the globe, followed by intravitreal injection of the Avastin from a site 3.5 millimeter posterior to the limbus. The dose we administered was one milligram of bevacizumab (0.04 mL of 25 mg/mL).
Study: NCT02084368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Patients will be assigned to receive lumbar plexus block and sciatic nerve block both using 0.33% ropivacain 30ml guided by PNS.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: Combined spinal and epidural anesthesia will be performed in patients with 0.5% hyperbaric bupivacaine 8\~10mg.
Study: NCT04991012

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PDT Therapy
Description: the olp was photosensitized with methylen blue and was irradiated with a semiconductor laser with a wavelength of 650 nm, using a dose of 120 J / cm2 and power density
Study: NCT01051583

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Diode laser cyclophotocoagulation enhanced by intravitreal injection of Avastin
Description: The operative procedure involved retro-bulbar anesthesia, draping the patient in an aseptic manner, introduction of an eye speculum, 30 laser shots over 270 degrees of the circumference of the limbus. For our study we used the Iris Diode laser machine, the G-probe and we adjusted the settings for 2500 millisecond duration and the 3000 milli-joule and reduced the power progressively until just below the energy level that produced a pop.then after applying the laser, we performed a paracentesis with a 27 gauge needle to soften the globe, followed by intravitreal injection of the Avastin from a site 3.5 millimeter posterior to the limbus. The dose we administered was one milligram of bevacizumab (0.04 mL of 25 mg/mL).
Study: NCT02286999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B. infantis
Description: Infants in the intervention group will receive two doses of B. infantis on Day 7 and Day 14 of life, while infants in the placebo group will be dosed with placebo on Day 7 and Day 14

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04991012

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone (Substance) therapy side
Description: th The OLP on the other side was treated by daily sticking a cut-to-size carrier with 0.05% triamcinolone acetonide for 8 days
Study: NCT01008137

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H1N1 influenza A Vaccine (PANFLU.1)
Description: H1N1 influenza A Vaccine (PANFLU.1), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H1N1 influenza A Vaccine (PANFLU.1)
Description: H1N1 influenza A Vaccine (PANFLU.1), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm)
Study: NCT02777632

Intervention type: PROCEDURE
Intervention: Living donor liver transplantation

Intervention type: PROCEDURE
Intervention: Living donor liver transplantation
Study: NCT04768361

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation without Mindfulness
Description: Behavioral Activation without Mindfulness includes functional analysis as key to defining out-of-session and activation strategies as central to mood change.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation with Mindfulness
Description: Behavioral Activation with Mindfulness includes functional analysis as key to defining out-of-session and activation strategies and mindfulness as central to mood change.
Study: NCT01934829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: urea-based cream
Description: urea-based cream (10% urea; Eucerin) 3 times per day plus best supportive care, starting on day 1 of sorafenib treatment, for a maximum of 12 weeks .~BSC included the ad libitum use of non-urea-based moisturizing creams, alcohol-free moisturizer and petroleum jelly. Once HFSR occurred, patients were allowed any cream, including urea based creams, as guided by the investigator.
Study: NCT00588965

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given 1 pill daily for a week, then 2 pills daily, followed by the exercise test.
Study: NCT00567554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin - cyclophosphamide / docetaxel + trastuzumab
Study: NCT00588965

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol LA
Description: Subjects will receive propranolol LA 80 mg one pill daily for 1 week then 2 pills daily for 1 week followed by exercise test.
Study: NCT04490148

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: remote pulmonary function testing
Description: Telemedicine delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)
Study: NCT01008137

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H1N1 influenza A Vaccine (PANFLU.1)
Description: H1N1 influenza A Vaccine (PANFLU.1), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Inactivated Influenza Vaccine (ANFLU)
Description: Trivalent Inactivated Influenza Vaccine (ANFLU), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (injected in the other arm)
Study: NCT00567554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin - cyclophosphamide / docetaxel + lapatinib
Study: NCT03254810

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SYN060
Description: a single subcutaneous 0.57 mg/kg dose of SYN060

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab North American source
Description: a single subcutaneous 0.57 mg/kg dose of adalimumab (Humira®) reference product from North American source

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab European source
Description: a single subcutaneous 0.57 mg/kg dose of adalimumab (Humira®) reference product from European source
Study: NCT04565730

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Grup I= General anesthesia group
Description: Preoperative and postoperative evaluation Pre-operative data will be collected 1 to 2 hrs before operation. Preoperative anxiety level will be assessed by the Hospital Anxiety and Depression Scale (HADS) and Amsterdam Preoperative Anxiety and Information Scale.~Patients will be asked to complete the Edinburgh Postnatal Depression Scale (EPDS) on the morning of discharge, 1 months and 3 months days after delivery. An online survey will be conducted post-Cesarean delivery to investigate the primary outcome of PND using EPDS, and those will not complete the online survey received phone calls to conduct the follow-up surveys.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Grup II= Spinal anesthesia group
Description: Preoperative and postoperative evaluation Pre-operative data will be collected 1 to 2 hrs before operation. Preoperative anxiety level will be assessed by the Hospital Anxiety and Depression Scale (HADS) and Amsterdam Preoperative Anxiety and Information Scale.~Patients will be asked to complete the Edinburgh Postnatal Depression Scale (EPDS) on the morning of discharge, 1 months and 3 months days after delivery. An online survey will be conducted post-Cesarean delivery to investigate the primary outcome of PND using EPDS, and those will not complete the online survey received phone calls to conduct the follow-up surveys.
Study: NCT01082939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2/day IV on Days 3-5; repeated every four weeks for a total of 6 planned cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 250 mg/m\^2/day IV on Days 3-5; repeated every four weeks for a total of 6 planned cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: 30 mg IV on Days 1, 3 and 5 over 2-4 hours; repeated every four weeks for a total of 6 planned cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Cycle 1 (Week 1): 375 mg/m\^2/day IV on Day 2 over 4- 6 hours~Cycle 2 - 6 (Week 1): 500 mg/m\^2/day IV on Day 2 over 4- 6 hours
Study: NCT04490148

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: remote pulmonary function testing
Description: Telemedicine delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)
Study: NCT01008137

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Inactivated Influenza Vaccine (ANFLU)
Description: Trivalent Inactivated Influenza Vaccine (ANFLU), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (injected in the other arm)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Inactivated Influenza Vaccine (ANFLU)
Description: Trivalent Inactivated Influenza Vaccine (ANFLU), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (injected in the other arm)
Study: NCT02895555

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: i-FACTOR
Description: Between 5-10 CC i-FACTOR putty mixed with local harvested autograft pr level spondylodesis compared to 30 grams of allograft pr level mixed with local harvested allograft.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Allograft
Description: Approx 50 g of allograft bone in the fused site
Study: NCT04124757

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block
Description: Deep neuromuscular block will be achieved with high dose rocuronium to achieve a depth of 1-2 twitches post tetanic count
Study: NCT04490148

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: standard pulmonary function testing
Description: Standard clinical delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard pulmonary function testing
Description: Standard clinical delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse Respiratory Health Coaching (NRHC)
Description: Nurse Respiratory Health Coaching - The NRHC intervention follows the teamlet model described by Bennett et al. \[Bennett2010\], made up of the research coordinator who performs respiratory testing, and the nurse practitioner who coaches using the GROW (goals, realities, options, wrap-up) model.
Study: NCT04691973

Intervention type: BEHAVIORAL
Intervention: Health and lifestyle tool
Description: Health and lifestyle tool used online

Intervention type: OTHER
Intervention: Usual care
Description: Usual care at ordinary healthcare provider
Study: NCT03718793

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Peripheral exhaled nitric oxide
Description: Small airway inflammation and dysfunction will be measured using the above mentioned tests.
Study: NCT03610698

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LEAF Positive Emotion Intervention
Description: 5-week online intervention teaching 8 positive emotions skills for caregivers
Study: NCT02353637

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Partial Meal Replacements
Description: The use of partial meal replacements will be utilized in conjunction with a high protein, restricted carbohydrate diet
Study: NCT03610698

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LEAF Positive Emotion Intervention
Description: 5-week online intervention teaching 8 positive emotions skills for caregivers

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Emotion Reporting Control Condition
Description: Daily reporting of emotions for participants assigned to the control condition.
Study: NCT04103736

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beet It Sport Shot
Description: Source of naturally occurring dietary nitrates

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nitrate-depleted placebo
Description: Placebo
Study: NCT03817736

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: Procedure of TACE will be standardized.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT screening and planning will be performed by radiation therapists, medical physicists, and oncologists.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune Checkpoint Inhibitor
Description: An immune checkpoint inhibitor may be administered up to 3 days before or after the scheduled day of administration of each cycle due to administrative reasons.
Study: NCT03248011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching
Description: Lower extremity flexibility exercises will be performed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening
Description: Eccentric hamstring strengthening exercises will be performed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular
Description: Dynamic lower extremity balance and movement control exercises will be performed
Study: NCT00431808

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Malaria vaccine AMA1 (PfAMA-1-FVO[25-545]
Description: 3 doses of AMA 1 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMA1
Description: 50 micrograms of AMA1
Study: NCT03948659

Intervention type: PROCEDURE
Intervention: Arterio ventricular coupling
Description: We analyse ventriculo arterial coupling (VAC) among cirrhotic patients admitted in intensive care unit, with non-invasive echography method
Study: NCT04148924

Intervention type: OTHER
Intervention: Questionnaire
Description: Patients complete a questionnaire for assess their symptoms like anxiety and depression.~These questionnaires contains:~* socio-demographic characteristics : sex, age, type and stage of cancer, performans status~* ESAS : Edmonton Symptom Assessement Scale is a validated tool for assessment of several symptoms~* HADS - A : Hospital Anxiety and Depression scale includes 2 subscales which assess anxiety (HADS-A) and depression (HADS-D)~* BEDS : Brief Edimburg depression Scale is s a relevant scale for assess depression in palliative care patients.~* Questions on the assessment, the treatment and difficulties in management of anxious and depressive symptoms.~The evaluation will be realized in the first days of hospitalization (72 hours).

Intervention type: OTHER
Intervention: Medical staff questionnaire
Description: Questionnaire is different from caregivers. The evaluation will be realized in the first days of hospitalization (72 hours).~Physicians, nurses and caregivers complete another questionnaire. The physician questioned will be the doctor of unit having received the patient, or the doctor of the mobile team of palliative care having admitted the patient in the unit.~These questionnaires contains:~* socio-demographic characteristics : sex, age, type and stage of cancer, performans status~* ESAS : Edmonton Symptom Assessement Scale is a validated tool for assessment of several symptoms

Intervention type: OTHER
Intervention: Medical staff questionnaire
Description: Questionnaire is different from caregivers. The evaluation will be realized in the first days of hospitalization (72 hours).~Physicians, nurses and caregivers complete another questionnaire. The physician questioned will be the doctor of unit having received the patient, or the doctor of the mobile team of palliative care having admitted the patient in the unit.~These questionnaires contains:~* socio-demographic characteristics : sex, age, type and stage of cancer, performans status~* ESAS : Edmonton Symptom Assessement Scale is a validated tool for assessment of several symptoms
Study: NCT02592772

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced Nicotine Non-Menthol (RNC)
Description: Switch from own brand of cigarette to an investigational tobacco product with a reduced nicotine content of 0.07mg nicotine yield without menthol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced Nicotine Menthol (RNC-Men)
Description: Switch from own brand of cigarette to an investigational tobacco product with a reduced nicotine content of 0.07mg nicotine yield with menthol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Nicotine Non-Menthol (CN)
Description: Switch from own brand of cigarette to an investigational tobacco product which contains conventional nicotine yield.
Study: NCT02632175

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: every other week or weekly subcutaneous injection
Study: NCT02330952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 40mg/day per os for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 40mg/day per os for 5 days
Study: NCT03653026

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Upadacitinib
Description: Tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Tablet for oral administration
Study: NCT02405572

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: infant formula
Description: infant formulas

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: infant formula
Description: infant formulas